|
【结 构 式】 
|
【分子编号】53260 【品名】(1R,3S,5R)-3-{[tert-butyl(dimethyl)silyl]oxy}tricyclo[3.2.0.0~2,7~]heptan-6-one 【CA登记号】n/a |
【 分 子 式 】C13H22O2Si 【 分 子 量 】238.40198 【元素组成】C 65.5% H 9.3% O 13.42% Si 11.78% |
合成路线1
该中间体在本合成路线中的序号：(VI)Synthesis of the tricyclic ketone intermediate (VI): Optical resolution of racemic bicyclo[3.2.0]hept-2-en-6-one (I) by reaction with SO2 and (+)-a-methylbenzylamine (II) yields a mixture of diastereomeric salts of the a-hydroxysulfonic acid with the chiral amine (II), which are separated by crystallization. Treatment of the purified salt (III) with aqueous Na2CO3 results in the pure enantiomer ()-(I). Reaction of ()-(I) with 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) in acetone/water affords the bromohydrin (IV), which is treated with TBDMS-Cl and imidazole to provide the silyl ether (V). Finally, reaction of the protected bromohydrin (V) with potassium tert-butoxide in toluene gives the target tricyclic ketone intermediate (VI).
| 【1】 Boulton, L.T.; Brick, D.; Fox, M.E.; et al.; Synthesis of the potent antiglaucoma agent, travoprost. Org Process Res Dev 2002, 6, 2, 138. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (-)-(I) | 24421 | (1S,5R)bicyclo[3.2.0]hept-2-en-6-one | C7H8O | 详情 | 详情 | |
| (rac)-(I) | 53261 | bicyclo[3.2.0]hept-2-en-6-one | 13173-09-6 | C7H8O | 详情 | 详情 |
| (II) | 10039 | (1R)-1-Phenylethylamine; (1R)-1-Phenyl-1-ethanamine.; L-alpha-Phenylethylamine | 3886-69-9 | C8H11N | 详情 | 详情 |
| (III) | 53267 | Butanoic acid; Butyric acid; N-Butanic acid; N-Butanoic acid; n-Butyric acid; N-Ethylacetic acid; N-Propanecarboxylic acid; N-Propylformic acid | 107-92-6 | C4H8O2 | 详情 | 详情 |
| (IV) | 53258 | (1R,2S,3S,5R)-2-bromo-3-hydroxybicyclo[3.2.0]heptan-6-one | n/a | C7H9BrO2 | 详情 | 详情 |
| (V) | 53259 | (1R,2S,3S,5R)-2-bromo-3-{[tert-butyl(dimethyl)silyl]oxy}bicyclo[3.2.0]heptan-6-one | n/a | C13H23BrO2Si | 详情 | 详情 |
| (VI) | 53260 | (1R,3S,5R)-3-{[tert-butyl(dimethyl)silyl]oxy}tricyclo[3.2.0.0~2,7~]heptan-6-one | n/a | C13H22O2Si | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(VI)Synthesis of the alkenyl cuprate (XVII): Enzymatic acylation of the racemic acetylenic alcohol (VII) with vinyl butyrate (VIII) by means of Chirazyme L9 gives a mixture of the ester (R)-(IX) and the alcohol (S)-(X). Reaction of this mixture with Ms-Cl and TEA yields a mixture of ester (R)-(IX) and the mesylate (S)-(XI). Treatment of this mixture with butyric acid and TEA results in the acylation of mesylate (S)-(XI) with optical inversion, providing pure ester (R)-(IX). Enzymatic hydrolysis of (R)-(IX) with Chirazyme L2 affords the enantiomerically pure alcohol (R)-(XIII). Silylation of alcohol (XIII) with TBDMS-Cl and imidazole gives the silyl ether (XIV), which is iodinated with Cp2ZrCl2 and I2 to yield the iodovinyl derivative (XV). Finally, the reaction of compound (XV) with the lithium cuprate (XVI) prepared by lithiation of thiophene with BuLi followed by treatment with copper (I) cyanide affords the alkenyl cuprate (XVII). Condensation of the alkenyl cuprate (XVII) with the tricyclic ketone (VI) in toluene provides the bicyclic ketone (XVIII), which is submitted to a Baeyer-Villiger oxidation with peracetic acid to give a mixture of the regioisomeric lactones (XIX) and (XX). The minor and unwanted regioisomer (XIX) is selectively hydrolyzed by treatment with aqueous Na2CO3 and separated by crystallization. Reduction of lactone (XX) with DIBAL in toluene gives lactol (XXI), which is submitted to a Wittig condensation with (4-carboxybutyl)triphenylphosphonium bromide and t-BuOK in THF, followed by esterification with isopropyl iodide and DBU, yielding a mixture of the monosilylated compounds (XXIII) and (XXIV) due to migration of the silyl group on the cyclopentane ring. Finally, this mixture is deprotected with HCl in isopropanol.
| 【1】 Boulton, L.T.; Brick, D.; Fox, M.E.; et al.; Synthesis of the potent antiglaucoma agent, travoprost. Org Process Res Dev 2002, 6, 2, 138. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VI) | 53260 | (1R,3S,5R)-3-{[tert-butyl(dimethyl)silyl]oxy}tricyclo[3.2.0.0~2,7~]heptan-6-one | n/a | C13H22O2Si | 详情 | 详情 |
| (VII) | 53262 | 1-[3-(trifluoromethyl)phenoxy]-3-butyn-2-ol | 88462-65-1 | C11H9F3O2 | 详情 | 详情 |
| (VIII) | 53263 | n-Butyric acid vinyl ester; Vinyl n-butyrate; Vinyl butyrate | 123-20-6 | C6H10O2 | 详情 | 详情 |
| (IX) | 53264 | (1R)-1-{[3-(trifluoromethyl)phenoxy]methyl}-2-propynyl butyrate | n/a | C15H15F3O3 | 详情 | 详情 |
| (X) | 53265 | (2S)-1-[3-(trifluoromethyl)phenoxy]-3-butyn-2-ol | n/a | C11H9F3O2 | 详情 | 详情 |
| (XI) | 53266 | (1S)-1-{[3-(trifluoromethyl)phenoxy]methyl}-2-propynyl methanesulfonate | n/a | C12H11F3O4S | 详情 | 详情 |
| (XII) | 53267 | Butanoic acid; Butyric acid; N-Butanic acid; N-Butanoic acid; n-Butyric acid; N-Ethylacetic acid; N-Propanecarboxylic acid; N-Propylformic acid | 107-92-6 | C4H8O2 | 详情 | 详情 |
| (XIII) | 53278 | (2R)-1-[3-(trifluoromethyl)phenoxy]-3-butyn-2-ol | n/a | C11H9F3O2 | 详情 | 详情 |
| (XIV) | 53268 | tert-butyl(dimethyl)[((1R)-1-{[3-(trifluoromethyl)phenoxy]methyl}-2-propynyl)oxy]silane; tert-butyl(dimethyl)silyl (1R)-1-{[3-(trifluoromethyl)phenoxy]methyl}-2-propynyl ether | n/a | C17H23F3O2Si | 详情 | 详情 |
| (XV) | 53269 | tert-butyl(dimethyl)silyl (1R,2E)-3-iodo-1-{[3-(trifluoromethyl)phenoxy]methyl}-2-propenyl ether; tert-butyl[((1R,2E)-3-iodo-1-{[3-(trifluoromethyl)phenoxy]methyl}-2-propenyl)oxy]dimethylsilane | n/a | C17H24F3IO2Si | 详情 | 详情 |
| (XVI) | 53270 | lithium cyano(2-thienyl)cuprate(1-) | n/a | C5H3CuLiNS | 详情 | 详情 |
| (XVII) | 53271 | n/a | C22H27CuF3Li2NO2SSi | 详情 | 详情 | |
| (XVIII) | 53272 | (5S)-5-{[tert-butyl(dimethyl)silyl]oxy}-7-{(E,3R)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-[3-(trifluoromethyl)phenoxy]-1-butenyl}bicyclo[2.2.1]heptan-2-one | n/a | C30H47F3O4Si2 | 详情 | 详情 |
| (XIX) | 53273 | (6S)-6-{[tert-butyl(dimethyl)silyl]oxy}-8-{(E,3R)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-[3-(trifluoromethyl)phenoxy]-1-butenyl}-3-oxabicyclo[3.2.1]octan-2-one | n/a | C30H47F3O5Si2 | 详情 | 详情 |
| (XX) | 53274 | (6S)-6-{[tert-butyl(dimethyl)silyl]oxy}-8-{(E,3R)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-[3-(trifluoromethyl)phenoxy]-1-butenyl}-2-oxabicyclo[3.2.1]octan-3-one | n/a | C30H47F3O5Si2 | 详情 | 详情 |
| (XXI) | 53275 | (6S)-6-{[tert-butyl(dimethyl)silyl]oxy}-8-{(E,3R)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-[3-(trifluoromethyl)phenoxy]-1-butenyl}-2-oxabicyclo[3.2.1]octan-3-ol | n/a | C30H49F3O5Si2 | 详情 | 详情 |
| (XXII) | 13616 | (4-Carboxybutyl)triphenylphosphonium bromide | 17814-85-6 | C23H24BrO2P | 详情 | 详情 |
| (XXIII) | 53276 | isopropyl (Z)-7-((1R,2R,3R,5S)-5-{[tert-butyl(dimethyl)silyl]oxy}-2-{(E,3R)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-[3-(trifluoromethyl)phenoxy]-1-butenyl}-3-hydroxycyclopentyl)-5-heptenoate | n/a | C38H63F3O6Si2 | 详情 | 详情 |
| (XXIV) | 53277 | isopropyl (Z)-7-((1R,2R,3R,5S)-3-{[tert-butyl(dimethyl)silyl]oxy}-2-{(E,3R)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-[3-(trifluoromethyl)phenoxy]-1-butenyl}-5-hydroxycyclopentyl)-5-heptenoate | n/a | C38H63F3O6Si2 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(VIII)The first method required the chiral building block (S)-(4-fluorophenyl)glycine (VI), which was prepared from 4-fluorophenyl acetic acid (I) by two routes. Condensation of (I) with (S)-4-benzyl-2-oxazolidinone (II), via activation as the corresponding mixed anhydride with pivaloyl chloride, furnished the N-acyl oxazolidinone (III). The potassium enolate of (III) was then reacted with 2,4,6-triisopropylphenylsulfonyl azide, producing stereoselectively azide (IV). Hydrolytic removal of the chiral auxiliary of (IV) gave (S)-azido-(4-fluorophenyl)acetic acid (V), which was then reduced to the desired amino acid (VI) by catalytic hydrogenation over Pd/C. Alternatively, 4-fluorophenyl acetic acid (I) was converted to the corresponding acid chloride (VII) with SOCl2. Bromination of (VII) under Hell-Volhard-Zelinskii conditions, followed by quenching with MeOH, afforded the racemic alpha-bromo ester (VIII). Displacement of the bromide of (VIII) with NaN3 using a phase-transfer catalyst produced the azido ester (IX). Catalytic hydrogenation of the azido group of (IX) gave the racemic amino ester, which was resolved via formation of the diastereomeric salts with (+)-dibenzoyltartaric acid. The desired (S)-amino ester (X) was then hydrolyzed to (VI) under acidic conditions.
| 【1】 Baker, R.; Harrison, T.; Mcleod, A.M.; Owens, A.P.; Seward, E.M.; Swain, C.J.; Teall, M.R. (Merck Sharp & Dohme Ltd.); Substd. morpholine derivs. and their use as therapeutic agents. EP 0737192; EP 1099702; JP 1997507484; JP 2000219629; US 5612337; WO 9518124 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 18999 | 4-Fluorophenylacetic acid; 2-(4-Fluorophenyl)acetic acid | 405-50-5 | C8H7FO2 | 详情 | 详情 |
| (II) | 14694 | (S)-4-Benzyl-2-oxazolidinone; (4S)-4-Benzyl-1,3-oxazolan-2-one; (S)-(-)-4-Benzyl-2-oxazolidinone | 90719-32-7 | C10H11NO2 | 详情 | 详情 |
| (III) | 44186 | (4S)-4-benzyl-3-[2-(4-fluorophenyl)acetyl]-1,3-oxazolidin-2-one | C18H16FNO3 | 详情 | 详情 | |
| (IV) | 44188 | (4S)-3-[(2S)-2-azido-2-(4-fluorophenyl)ethanoyl]-4-benzyl-1,3-oxazolidin-2-one | C18H15FN4O3 | 详情 | 详情 | |
| (V) | 44189 | (2S)-2-azido-2-(4-fluorophenyl)ethanoic acid | C8H6FN3O2 | 详情 | 详情 | |
| (VI) | 37104 | (8R,9S,10R,13S,14S,17S)-17-hydroxy-2-[(Z)-hydroxymethylidene]-4,10,13,17-tetramethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one | C22H32O3 | 详情 | 详情 | |
| (VII) | 44191 | methyl 2-bromo-2-(4-fluorophenyl)acetate | C9H8BrFO2 | 详情 | 详情 | |
| (VIII) | 53260 | (1R,3S,5R)-3-{[tert-butyl(dimethyl)silyl]oxy}tricyclo[3.2.0.0~2,7~]heptan-6-one | n/a | C13H22O2Si | 详情 | 详情 |
| (IX) | 53261 | bicyclo[3.2.0]hept-2-en-6-one | 13173-09-6 | C7H8O | 详情 | 详情 |
| (X) | 43098 | (2R)-2-amino-2-(4-fluorophenyl)ethanoic acid | 7292-73-1 | C8H8FNO2 | 详情 | 详情 |